SeekingAlpha · Mar 10, 2026
Nuwellis, Inc. (NUWE) Q4 2025 Earnings Call Transcript
Nuwellis, Inc. (NUWE) Q4 2025 Earnings Call March 10, 2026 9:00 AM EDTCompany ParticipantsLeah McMullen - Director of CommunicationsJohn Erb - CEO,...
NASDAQ · NUWE
Healthcare · Medical - Devices
$1.19
Down-$0.07 (-5.56%)
Updated Aug 19, 2026, 6:14 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
NUWE does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning NUWE.
NUWE research
Company profile and research snapshot.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2024 | Roth MKM | Buy | — |
| Jul 29, 2024 | Roth MKM | Buy | — |
| Nov 8, 2023 | Ladenburg Thalmann | Neutral | — |
No generated briefing is available yet.
SeekingAlpha · Mar 10, 2026
Nuwellis, Inc. (NUWE) Q4 2025 Earnings Call March 10, 2026 9:00 AM EDTCompany ParticipantsLeah McMullen - Director of CommunicationsJohn Erb - CEO,...
ChartMill · Mar 10, 2026
Nuwellis stock surges after Q4 earnings beat estimates, with revenue and EPS exceeding analyst expectations.
Benzinga · Mar 10, 2026
Nuwellis (NASDAQ:NUWE) reported quarterly losses of $(1.50) per share which beat the analyst consensus estimate of $(1.56) by 3.85 percent. This is a 91.8 percent increase over losses of $(18.30) per share from the same
Benzinga · Mar 9, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning NUWE.